These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32375555)

  • 1. High serum free IL-18 is associated with decreased omalizumab efficacy: findings from a 2-year omalizumab treatment study.
    Morimoto C; Matsumoto H; Tajiri T; Gon Y; Ito R; Hashimoto S; Suzukawa M; Ohta K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Kanemitsu Y; Nagasaki T; Izuhara Y; Niimi A; Hirai T
    J Asthma; 2021 Sep; 58(9):1133-1142. PubMed ID: 32375555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab.
    Suzukawa M; Matsumoto H; Ohshima N; Tashimo H; Asari I; Tajiri T; Niimi A; Nagase H; Matsui H; Kobayashi N; Shoji S; Ohta K
    Respir Med; 2018 Jan; 134():95-102. PubMed ID: 29413515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
    Akenroye A; Nopsopon T; Hacker JJ; Laidlaw TM
    Sci Rep; 2024 May; 14(1):10404. PubMed ID: 38710930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
    Kupryś-Lipińska I; Molińska K; Kuna P
    Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
    J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IgE Significantly Changes Circulating Interleukin-25, Vitamin-D and Interleukin-33 Levels in Patients with Allergic Asthma.
    Yalcin AD; Uzun R
    Curr Pharm Des; 2019; 25(35):3784-3795. PubMed ID: 31566129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study.
    Djukanović R; Brinkman P; Kolmert J; Gomez C; Schofield J; Brandsma J; Shapanis A; Skipp PJS; Postle A; Wheelock C; Dahlen SE; Sterk PJ; Brown T; Jackson DJ; Mansur A; Pavord I; Patel M; Brightling C; Siddiqui S; Bradding P; Sabroe I; Saralaya D; Chishimba L; Porter J; Robinson D; Fowler S; Howarth PH; Little L; Oliver T; Hill K; Stanton L; Allen A; Ellis D; Griffiths G; Harrison T; Akenroye A; Lasky-Su J; Heaney L; Chaudhuri R; Kurukulaaratchy R;
    Am J Respir Crit Care Med; 2024 Aug; 210(3):288-297. PubMed ID: 38635834
    [No Abstract]   [Full Text] [Related]  

  • 15. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
    Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
    Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
    Zhu R; Zheng Y; Putnam WS; Visich J; Eisner MD; Matthews JG; Rosen KE; D'Argenio DZ
    AAPS J; 2013 Apr; 15(2):559-70. PubMed ID: 23413101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.